DE-122 (Carotegrast methyl)
Ulcerative Colitis
Phase 3Active
Key Facts
About Rohto Pharmaceutical
Rohto Pharmaceutical is a major Japanese healthcare company with a century-long history, specializing in OTC eye care, prescription pharmaceuticals, and consumer health products. Its strategic focus includes expanding its global footprint, particularly in Asia and the Americas, and advancing a pipeline of novel therapeutics in ophthalmology and dermatology. The company's strength lies in its powerful consumer brands, robust R&D capabilities in formulation technology, and a diversified business model that balances stable OTC revenue with growth from innovative prescription drugs.
View full company profileOther Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Mirikizumab | Eli Lilly | Phase 3 |
| Filgotinib | Gilead Sciences | Phase 3 |
| Obefazimod (ABX464) | Abivax | Phase 3 |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Phase 3 |
| DE-130 (Etrasimod) | Rohto Pharmaceutical | Phase 3 |
| Methylene Blue MMX® | Cosmo Pharmaceuticals | Preclinical |
| KRP-203 (Amiselimod) | Kissei Pharmaceutical | Phase II |
| EVO301 | Evommune | Phase 1 |
| Pentasa (Mesalazine) | Zeria Pharmaceutical | Approved/Commercial |
| SER-301 | Seres Therapeutics | Phase 1b |
| SER-287 | Seres Therapeutics | Phase 2b |
| IMP731 | Immutep | Phase 2 |